<table border="0" cellpadding="0" cellspacing="0" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">Drugs That Interfere with  Hemostasis</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> •  Celecoxib and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of Celecoxib and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.<br/>             •  Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> Monitor patients with concomitant use of celecoxib with anticoagulants (e.g., warfarin), antiplatelet  agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine  reuptake inhibitors (SNRIs) for signs of bleeding [<content stylecode="italics">see Warnings and Precautions  (5.11)</content>].</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">Aspirin</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin  does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the  concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse  reactions as compared to use of the NSAID alone [<content stylecode="italics">see Warnings and Precautions  (5.2)</content>].<br/>
<content stylecode="bold"> </content>In two studies in healthy volunteers, and in patients with osteoarthritis and established heart  disease respectively, celecoxib (200 to 400 mg daily) has demonstrated a lack of interference with the  cardioprotective antiplatelet effect of aspirin (100 to 325  mg).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> Concomitant use of celecoxib and analgesic doses of aspirin is not generally recommended because of  the increased risk of bleeding [<content stylecode="italics">see Warnings and Precautions  (5.11)</content>].<br/>Celecoxib is not a substitute for low dose aspirin for cardiovascular  protection.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">ACE  Inhibitors,  Angiotensin  Receptor  Blockers,  and  Beta-Blockers</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> •  NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).<br/>             •  In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> •  During concomitant use of celecoxib and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.<br/>             •  During concomitant use of celecoxib and ACE-inhibitors or ARBs in patients who are elderly, volume- depleted, or have impaired renal function, monitor for signs of worsening renal function [see Warnings and Precautions (5.6)].<br/>             •  When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect  of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to  the NSAID inhibition of renal prostaglandin  synthesis.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> During concomitant use of celecoxib with diuretics, observe patients for signs of worsening renal  function, in addition to assuring diuretic efficacy including antihypertensive effects [<content stylecode="italics">see Warnings and  Precautions (5.6)</content>].</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">Digoxin</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> The concomitant use of Celecoxib with digoxin has been reported to increase the serum concentration  and prolong the half-life of  digoxin.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> During concomitant use of celecoxib and digoxin, monitor serum digoxin  levels.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">Lithium</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance<content stylecode="italics">.  </content>The mean minimum lithium concentration increased 15%, and the renal clearance decreased by  approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin  synthesis.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> During concomitant use of celecoxib and lithium, monitor patients for signs of lithium  toxicity.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">Methotrexate</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity  (e.g., neutropenia, thrombocytopenia, renal  dysfunction).<br/>
<content stylecode="bold"> </content>Celecoxib has no effect on methotrexate  pharmacokinetics.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> During concomitant use of celecoxib and methotrexate, monitor patients for methotrexate  toxicity.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">Cyclosporine</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> Concomitant use of celecoxib and cyclosporine may increase cyclosporine’s  nephrotoxicity.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> During concomitant use of celecoxib and cyclosporine, monitor patients for signs of worsening  renal function.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">NSAIDs and  Salicylates</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> Concomitant use of Celecoxib with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk  of GI toxicity, with little or no increase in efficacy [<content stylecode="italics">see Warnings and Precautions  (5.2)</content>]<content stylecode="italics">.</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> The concomitant use of Celecoxib with other NSAIDs or salicylates is not  recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">Pemetrexed</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> Concomitant use of celecoxib and pemetrexed may increase the risk of  pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing  information).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Intervention:</content>
</td>
<td align="justify" stylecode="Rrule" valign="middle"> During concomitant use of celecoxib and pemetrexed, in patients with renal impairment whose  creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI  toxicity.<content stylecode="bold"> </content>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of  two days before, the day of, and two days following administration of  pemetrexed.<content stylecode="bold"> </content>
<br/>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer  half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five  days before, the day of, and two days following pemetrexed  administration.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">CYP2C9 Inhibitors or  inducers</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">  <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> Celecoxib metabolism is predominantly mediated via cytochrome P450 (CYP) 2C9 in the liver.  Co­administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g. fluconazole) may  enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g.  rifampin) may lead to compromised efficacy of  celecoxib.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> Evaluate each patient's medical history when consideration is given to prescribing celecoxib. A  dosage adjustment may be warranted when celecoxib is administered with CYP2C9 inhibitors or inducers.  [<content stylecode="italics">see Clinical Pharmacology  (12.3)</content>].</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">CYP2D6  substrates</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> <content stylecode="italics">In vitro </content>studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6.  Therefore, there is a potential for an <content stylecode="italics">in vivo </content>drug interaction with drugs that are metabolized by CYP2D6  (e.g. atomoxetine), and celecoxib may enhance the exposure and toxicity of these  drugs.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle">  <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> Evaluate each patient’s medical history when consideration is given to prescribing celecoxib. A  dosage adjustment may be warranted when celecoxib is administered with CYP2D6  substrates. [<content stylecode="italics">see Clinical Pharmacology  (12.3)</content>].</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle"> <content stylecode="bold">Corticosteroids</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Clinical  Impact:</content>
</td>
<td stylecode="Rrule" valign="middle"> Concomitant use of corticosteroids with celecoxib may increase the risk of GI ulceration or  bleeding.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="middle"> <content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Rrule" valign="middle"> Monitor patients with concomitant use of celecoxib with corticosteroids for signs of bleeding  [<content stylecode="italics">see Warnings and Precautions  (5.2)</content>].</td>
</tr>
</tbody>
</table>